Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.50 |
| ▸ | HTR2C | P28335 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 6/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12075520 | 0.84 | CCR5 (0.43) | HTR2AHTR2CHTTCCR5MAPT | |
| SCHEMBL12005166 | 0.84 | GAA (0.50) | HTR2AHTR2CL3MBTL1HTTMCHR1 | |
| SCHEMBL12005036 | 0.79 | CCR5 (0.50) | HTR2AHTR2CHTTCCR5 | |
| SCHEMBL12004803 | 0.77 | NPY5R (0.47) | HTR2AHTR2CHTTCCR5MAPT | |
| SCHEMBL12004406 | 0.77 | HTR2A (0.48) | HTR2AHTR2CHTTCCR5MAPT | |
| SCHEMBL12006140 | 0.76 | HTT (0.56) | HTR2AHTR2CHTTCCR5MAPT | |
| SCHEMBL18686195 | 0.76 | HTR2A (0.50) | HTR2AHTR2CL3MBTL1HTTCCR5 | |
| SCHEMBL18686204 | 0.75 | GHSR (0.54) | HTR2AHTT | |
| SCHEMBL12004926 | 0.74 | GHSR (0.61) | HTR2AHTR2CHTTMCHR1CCR5 | |
| SCHEMBL12004560 | 0.74 | GHSR (0.51) | HTR2AHTR2CHTTMCHR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | claimed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | claimed |
| EP-2678017-B1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-04-05 | — | — | EP | claimed |
| US-20140121210-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2014-05-01 | — | — | US | claimed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | claimed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | claimed |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA | 2019-09-10 | — | — | US | disclosed |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA | 2019-09-10 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2018-02-15 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| US-9751836-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-05 | — | — | US | disclosed |
| EP-2678017-B1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-04-05 | — | — | EP | disclosed |
| US-20140121210-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2014-05-01 | — | — | US | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8658797-B2 | Asymmetric ureas and medical uses thereof | HELSINN HEALTHCARE SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | disclosed |
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220629-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | HTR2A 619/4885HTR2C 840/4885L3MBTL1 4196/4885 |
| US-10407390-B2 | Asymmetric ureas and medical uses thereof | UTS2R, GPR119, GHSR | HTR2A 619/4885HTR2C 840/4885L3MBTL1 4196/4885 |
| US-20140121210-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | HTR2A 619/4885HTR2C 840/4885L3MBTL1 4196/4885 |
| US-20180044293-A1 | ASYMMETRIC UREAS AND MEDICAL USES THEREOF | UTS2R, GPR119, GHSR | HTR2A 619/4885HTR2C 840/4885L3MBTL1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.